Cortagen vs Cardiogen: comparing the evidence, not just the marketing

Cortagen and Cardiogen come from the same Khavinson bioregulator family, share the same theoretical mechanism, and get lumped together constantly in peptide forums as if they're interchangeable options from the same shelf. They are not. Short answer: Cortagen has a real, if imperfect, human clinical record behind it, while Cardiogen's evidence base is thin and partly built on a citation mix-up that has nothing to do with the peptide itself.

I get versions of this question from clients who found both compounds on the same supplier list and assumed the site's "9 human studies" badge next to Cardiogen meant the two peptides were roughly equivalent in how well-tested they are. They are not equivalent, and the gap matters if you're deciding where to put your money.

What each peptide actually targets

Both are tetrapeptide-style Khavinson bioregulators, the Soviet-era research family built on the idea that short tissue-derived peptides cross into the nucleus and bind DNA promoter regions to modulate gene expression in a tissue-specific way. In-vitro work on the broader mechanism supports that nuclear-penetration claim at the family level, though it wasn't run on Cardiogen specifically.

Cortagen is aimed at cortical neurons. It's a cognitive bioregulator, with a claimed onset over a 10 to 20 day cycle and effects the Russian literature says persist for two to three months afterward. Cardiogen is aimed at cardiomyocytes, positioned as cardiovascular support in the same family as vesugen.

That's where the similarity ends. Where Cortagen has actual post-stroke clinical data in humans (unblinded, methodologically weak by Western standards, but real signal in real patients), Cardiogen doesn't have a comparable human trial to point to. The "Moderate, 9 human studies" figure that shows up on some peptide directories for Cardiogen is a name-collision artifact: those PubMed hits are about "CardioGen-82," a rubidium-82 cardiac imaging generator, plus an unrelated Hungarian cardiomyopathy registry that happened to use the word Cardiogen in its name. Neither has anything to do with this peptide's effect on cardiac tissue in a living person. I try to stay evidence-based with peptides, and passing along a mismatched citation as if it validates a compound is exactly the kind of thing that erodes trust in this whole space.

Cost, dosing, and cycle structure

Both peptides run on the same Khavinson cycling logic: short courses, long rest periods, repeated two to three times a year rather than daily maintenance dosing. Cortagen's cognitive protocol generally lands around 200 to 400 mcg subcutaneously for a 10 to 20 day cycle. Cardiogen's community dosing (100 to 200 mcg per day over a similar cycle length) is borrowed straight from the broader family convention because no Cardiogen-specific dose-finding work exists to confirm it fits this particular peptide.

The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.

Price-wise, Cardiogen tends to sit at a similar or slightly lower price point than Cortagen when you find it at all, but that's not a discount worth chasing. You're paying research-compound prices for a peptide with almost no independent literature to check a seller's purity claims against.

Side effects and the risk that actually matters here

Neither peptide shows a documented pattern of serious adverse events. Cortagen's Russian literature reports infrequent injection-site reactions and transient mild headache early in a cycle. Cardiogen's reported profile is described the same way, but that description leans on family-wide data rather than anything specific to the compound, because the specific data doesn't exist yet.

The bigger risk for both is what's in the vial. Khavinson-family peptides are one of the most heavily counterfeited categories in this market, and Cardiogen's thin published record makes a bad batch even harder to catch, since there's so little independent literature to compare a seller's identity and purity claims against. I've seen this pattern play out with clients before: a compound with weak evidence attracts weak quality control, because there's less scrutiny to keep vendors honest. If you're going to run either peptide, a third-party Certificate of Analysis confirming identity and purity above 99% is not optional.

Who each one actually suits

If you're chasing cognitive support with a real (if imperfect) human data trail behind the mechanism, Cortagen is the more defensible choice of the two. The post-stroke Russian data isn't a Western RCT, and I won't pretend it is, but it's a genuine clinical signal in real patients, layered on top of animal work showing improved Morris water maze performance and hippocampal BDNF increases.

If you're looking at Cardiogen for cardiovascular support, you should go in knowing you're working from theory and family-level extrapolation, not peptide-specific proof. The Khavinson framework has produced peptides like Thymalin with real clinical use in Russia, so the underlying idea has some track record behind it. But for cardiovascular goals specifically, I'd rather see clients put their research budget toward a compound with an actual human trial attached to it, and treat Cardiogen as speculative until better data shows up.

If your goal is broader energy, fatigue, or metabolic support rather than a targeted cardiac or cognitive effect, it's worth looking outside this family entirely. 5-Amino-1MQ works through a completely different mechanism and has its own separate evidence base worth reading before you commit to either Khavinson peptide.

I've had clients ask me why anyone would even carry Cardiogen given how thin the record is, and I think it's a bet on the Khavinson theory itself rather than on this specific molecule's proven results. That's a fine thing to know going in. It's a very different thing than believing the directory badge that says it already has nine human studies behind it.